An observational study in Heartburn, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-09-26.
Sponsored by AstraZeneca · Observational
The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage (as determined by the treating physician).
99 studies on the registry are indexed under Heartburn; 10 are open to participants now.
This study's planned enrollment of 1,220 is above the median of 728 across 17 observational studies indexed under Heartburn.
Browse Heartburn studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients presenting at general practitioner
Patient is using an NSAID** with the following conditions:
(**)OTC or Prescription NSAID
(**)Conventional NSAID or COX-2 selective NSAID
Exclusion Criteria:
No study locations are listed for this record.
This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca